ELUT
Elutia Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.82
−2.24%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
Market Cap
$36.37M
MomentumView details →
1D Return
−2.24%
YTD Return
+21.68%
RSI (14)
41.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
Market Cap
$36.37M
RSI (14)
41.7
MomentumView details →
1D Return
−2.24%
YTD Return
+21.68%
SummaryUpdated Jun 1, 2026
Elutia Inc. (NASDAQ:ELUT) is a commercial-stage biotechnology company founded in 2015 and headquartered in Silver Spring, Maryland. Originally incorporated as Aziyo Biologics, the company rebranded to Elutia in September 2023. The company went public in October 2020 and specializes in developing and commercializing drug-eluting biologics products for critical medical applications including cardiac device protection, wound care, and breast reconstruction. Elutia operates through three main business segments: Device Protection, Women's Health, and Cardiovascular, serving hospitals and healthcare facilities across the United States through direct sales forces, independent agents, and distributors.
Similar companies
Latest newsMore news →
Elutia Inc. completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for up to $11 million in cash, including $8 million at closing and up to $3 million in milestone payments.17d agoElutia Inc. secured a $15 million loan financing agreement with Avenue Capital Group, with $10 million funded at closing and a second $5 million tranche to be unlocked upon FDA 510(k) clearance of NXT-41x, to fund the launch of its antibiotic-eluting biomatrix in the plastic and reconstructive surgery market.22d ago